Personalized support for coverage, financial needs, and education—at every step of your treatment journey
Please see Important Safety Information, including important warning for risk of anaphylaxis, below and in the full Prescribing Information linked at the top of this page.
Your one-to-one support helps you:
Your one-to-one partner is here to:
A guide to help you find assistance for staying on treatment with VIMIZIM while traveling abroad
A comprehensive resource to help you understand how insurance plans work
A comprehensive guide to help you advocate for drug coverage
Complete the Patient Consent Form (PCF), which authorizes your doctor and health insurance to share your information with BioMarin.
Your BioMarin Clinical Coordinator will reach out to get you started.
Your doctor will also need to submit the Patient Enrollment Form (PEF) to complete your enrollment.
Once enrolled, your BioMarin RareConnections Case Manager will reach out about coverage and options to help you pay for your treatment.
Your health insurance sets your co-pay cost based on your coverage. If you qualify, the Co-Pay Assistance Program may lower what you pay for VIMIZIM.
*Only for commercially insured patients. Eligibility criteria and other program requirements apply. Click here for full Terms and Conditions.
Call us Monday-Friday, 8AM-8PM ET, at 1-866-906-6100.
What is the most important information I should know about VIMIZIM?
Severe and life-threatening hypersensitivity reactions, including anaphylaxis, can occur during any VIMIZIM infusion, as early as 30 minutes from the start and up to 6 days after infusion, and as late into treatment as the 47th infusion. These reactions can occur in people receiving VIMIZIM for the first time or in people who have previously received VIMZIM without having an allergic reaction.
Your doctor will tell you about the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and when to seek immediate medical care. Typical signs of anaphylaxis include cough, rash, throat tightness, hives, flushing, changes in skin color, low blood pressure, shortness of breath, chest pain, and gastrointestinal symptoms such as nausea, abdominal pain, retching, and vomiting. If a severe allergic reaction (e.g., anaphylaxis) occurs during infusion, the infusion should be stopped immediately, and you should receive medical attention. Contact your doctor or get medical help right away if these symptoms occur after VIMIZIM infusions.
If you have a respiratory illness, you may be at risk for a sudden worsening of your condition, and you may require additional monitoring.
What else should I know about Vimizim?
VIMIZIM is a prescription medicine. Before treatment with VIMIZIM, it is important to discuss your medical history with your doctor. Tell your doctor if you are sick or taking any medication and if you are allergic to any medicines. Also tell your doctor if you are pregnant, planning to become pregnant, or are a nursing mother. Your doctor will decide if VIMIZIM is right for you. If you have questions or would like more information about VIMIZIM, contact your doctor.
You should receive medication such as antihistamines before VIMIZIM infusions to reduce the risk of reactions. If a reaction occurs, the infusion should be slowed or stopped and you may be given additional medication. If a severe allergic reaction (e.g., anaphylaxis) occurs during infusion, the infusion should be stopped immediately, and you should receive medical treatment.
If you have acute febrile or respiratory illness at the time of VIMIZIM infusion, you may be at higher risk of life-threatening complications from hypersensitivity reactions. If you use supplemental oxygen or continuous positive airway pressure (CPAP), you should have it available during your infusion in the event of a sudden reaction, or extreme drowsiness/sleep from antihistamines.
Spinal cord damage may occur due to the natural MPS IVA disease process. Signs of spinal cord injury include back pain, numbness and paralysis of limbs, and loss of bladder and bowel control. Contact your doctor immediately if you develop any of these symptoms.
What are the most common side effects of VIMIZIM?
The most common side effects reported during VIMIZIM infusions included fever, vomiting, headache, nausea, abdominal pain, chills, and fatigue. These are not all the possible side effects with VIMIZIM. Talk to your doctor if you have any symptoms that bother you or that do not go away.
Call your doctor for medical advice about side effects. You may report side effects to BioMarin at 1-866-906-6100 and the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Please see full accompanying Prescribing Information, with important warning for risk of anaphylaxis or visit www.Vimizim.com.
What is VIMIZIM used for?
VIMIZIM® (elosulfase alfa) is indicated for patients with mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).